Unexpected staining patterns can arise from problems occurring in any of the steps required for IHC, some of which are discussed in part I of this CME series. Whether used to differentiate benign from malignant tumors, identify tumor subtypes, subtypes of hematopoietic malignancies, or identifying targets for therapy, the pathologist must be intimately familiar with the potential pitfalls that are inherent in the IHC methodology to troubleshoot problems in the laboratory, and more importantly, when interpreting immunohistochemical staining, to avoid pitfalls of false-positive or false-negative stains.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/DAD.0000000000000334 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Implications of a Dermatopathologist's Report on Melanoma Diagnosis and Treatment.
Life (Basel)
August 2023
Department of Plastic and Reconstructive Surgery, Sheba Medical Center, Tel-Hashomer, Ramat Gan 52621, Israel.
An accurate and comprehensive histopathology report is essential for cutaneous melanoma management, providing critical information for accurate staging and risk estimation and determining the optimal surgical approach. In many institutions, a review of melanoma biopsy specimens by expert dermatopathologists is considered a necessary step. This study examined these reviews to determine the critical primary histopathology Breslow score in which a histopathology review would be most beneficial.
View Article and Find Full Text PDFA Dermatopathologist's Guide to Troubleshooting Immunohistochemistry--Part 2: Troubleshooting Immunohistochemical Tests in the Laboratory.
Am J Dermatopathol
September 2015
*Dermatology Resident, Department of Dermatology, University of Illinois at Chicago, Chicago, IL; and †Laboratory Manager (J.N.T.), IHC HistoTechnician (M.M.M.), Dermatopathologist (J.M.J.-H.), Director (D.M.E.), Ackerman Academy of Dermatopathology, University of Illinois, Chicago, IL.
Unexpected staining patterns can arise from problems occurring in any of the steps required for IHC, some of which are discussed in part I of this CME series. Whether used to differentiate benign from malignant tumors, identify tumor subtypes, subtypes of hematopoietic malignancies, or identifying targets for therapy, the pathologist must be intimately familiar with the potential pitfalls that are inherent in the IHC methodology to troubleshoot problems in the laboratory, and more importantly, when interpreting immunohistochemical staining, to avoid pitfalls of false-positive or false-negative stains.
View Article and Find Full Text PDFA Dermatopathologist's Guide to Troubleshooting Immunohistochemistry Part 1: Methods and Pitfalls.
Am J Dermatopathol
August 2015
*Dermatology Resident, Department of Dermatology, University of Illinois at Chicago, Chicago, IL; and †Laboratory Manager (J.N.T.), IHC HistoTechnician (M.M.M.), Dermatopathologist (J.M.J.-H.), Director (D.M.E.), Ackerman Academy of Dermatopathology, University of Illinois, Chicago, IL.
Immunohistochemistry (IHC) is a method by which specific target antigens can be detected in formalin-fixed paraffin-embedded tissue and involves the use of monoclonal or polyclonal antibodies; visualization of specific tissue antigens is achieved through an enzymatic reaction that transforms a colorless chromogen to a colored one. These enzymes may be attached to the antibody through a protein-ligand method (eg, biotin-avidin or biotin-streptavidin) or through a secondary antibody. Epitopes that are masked by protein linkage during formalin fixation are unmasked using a retrieval system that either uses heat (heat-induced epitope retrieval) or proteolytic enzymes (proteolytic-induced epitope retrieval).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!